Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Market On-Q-ity's CTC Platform for Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – On-Q-ity today said that Laboratory Corporation of America will market the firm's circulating tumor cell platform to researchers in the biopharma industry.

According to the Waltham, Mass.-based firm, the technology will enable researchers to better stratify patients for potential inclusion or exclusion in clinical trials; more quickly identify patients eligible for study enrollment; better monitor cancer response to treatment; and use CTCs as an earlier indicator of treatment effectiveness.

"On-Q-ity’s CTC platform will provide researchers with a cost-effective, easy-to-use, and extremely accurate test to find and characterize tumor cells circulating in a patient’s blood," On-Q-ity CEO Mara Aspinall said in a statement.

Terms of the alliance were not disclosed.

On-Q-ity is one of several firms developing assays based on circulating tumor cells. Among the others are Advanced Cell Diagnostics and Biocept. Johnson & Johnson company Veridex already markets a circulating tumor cell test called the CellSearch system.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.